questionsmedicales.fr
Composés polycycliques
Composés macrocycliques
Lactames macrocycliques
Lactames macrocycliques : Questions médicales fréquentes
Termes MeSH sélectionnés :
{
"@context": "https://schema.org",
"@graph": [
{
"@type": "MedicalWebPage",
"name": "Lactames macrocycliques : Questions médicales les plus fréquentes",
"headline": "Lactames macrocycliques : Comprendre les symptômes, diagnostics et traitements",
"description": "Guide complet et accessible sur les Lactames macrocycliques : explications, diagnostics, traitements et prévention. Information médicale validée destinée aux patients.",
"datePublished": "2024-07-19",
"dateModified": "2025-04-15",
"inLanguage": "fr",
"medicalAudience": [
{
"@type": "MedicalAudience",
"name": "Grand public",
"audienceType": "Patient",
"healthCondition": {
"@type": "MedicalCondition",
"name": "Lactames macrocycliques"
},
"suggestedMinAge": 18,
"suggestedGender": "unisex"
},
{
"@type": "MedicalAudience",
"name": "Médecins",
"audienceType": "Physician",
"geographicArea": {
"@type": "AdministrativeArea",
"name": "France"
}
},
{
"@type": "MedicalAudience",
"name": "Chercheurs",
"audienceType": "Researcher",
"geographicArea": {
"@type": "AdministrativeArea",
"name": "International"
}
}
],
"reviewedBy": {
"@type": "Person",
"name": "Dr Olivier Menir",
"jobTitle": "Expert en Médecine",
"description": "Expert en Médecine, Optimisation des Parcours de Soins et Révision Médicale",
"url": "/static/pages/docteur-olivier-menir.html",
"alumniOf": {
"@type": "EducationalOrganization",
"name": "Université Paris Descartes"
}
},
"isPartOf": {
"@type": "MedicalWebPage",
"name": "Composés macrocycliques",
"url": "https://questionsmedicales.fr/mesh/D047028",
"about": {
"@type": "MedicalCondition",
"name": "Composés macrocycliques",
"code": {
"@type": "MedicalCode",
"code": "D047028",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D04.345"
}
}
},
"hasPart": [
{
"@type": "MedicalWebPage",
"name": "Maitansine",
"alternateName": "Maytansine",
"url": "https://questionsmedicales.fr/mesh/D008453",
"about": {
"@type": "MedicalCondition",
"name": "Maitansine",
"code": {
"@type": "MedicalCode",
"code": "D008453",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D04.345.295.500"
}
}
},
{
"@type": "MedicalWebPage",
"name": "Rifamycine",
"alternateName": "Rifamycins",
"url": "https://questionsmedicales.fr/mesh/D012294",
"about": {
"@type": "MedicalCondition",
"name": "Rifamycine",
"code": {
"@type": "MedicalCode",
"code": "D012294",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D04.345.295.750"
}
},
"hasPart": [
{
"@type": "MedicalWebPage",
"name": "Rifabutine",
"alternateName": "Rifabutin",
"url": "https://questionsmedicales.fr/mesh/D017828",
"about": {
"@type": "MedicalCondition",
"name": "Rifabutine",
"code": {
"@type": "MedicalCode",
"code": "D017828",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D04.345.295.750.650"
}
},
"hasPart": [
{
"@type": "MedicalWebPage",
"name": "Streptovarycine",
"alternateName": "Streptovaricin",
"url": "https://questionsmedicales.fr/mesh/D013310",
"about": {
"@type": "MedicalCondition",
"name": "Streptovarycine",
"code": {
"@type": "MedicalCode",
"code": "D013310",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D04.345.295.750.650.700"
}
}
}
]
},
{
"@type": "MedicalWebPage",
"name": "Streptovarycine",
"alternateName": "Streptovaricin",
"url": "https://questionsmedicales.fr/mesh/D013310",
"about": {
"@type": "MedicalCondition",
"name": "Streptovarycine",
"code": {
"@type": "MedicalCode",
"code": "D013310",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D04.345.295.750.650.700"
}
}
},
{
"@type": "MedicalWebPage",
"name": "Rifampicine",
"alternateName": "Rifampin",
"url": "https://questionsmedicales.fr/mesh/D012293",
"about": {
"@type": "MedicalCondition",
"name": "Rifampicine",
"code": {
"@type": "MedicalCode",
"code": "D012293",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D04.345.295.750.700"
}
}
},
{
"@type": "MedicalWebPage",
"name": "Rifaximine",
"alternateName": "Rifaximin",
"url": "https://questionsmedicales.fr/mesh/D000078262",
"about": {
"@type": "MedicalCondition",
"name": "Rifaximine",
"code": {
"@type": "MedicalCode",
"code": "D000078262",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D04.345.295.750.850"
}
}
}
]
}
],
"about": {
"@type": "MedicalCondition",
"name": "Lactames macrocycliques",
"alternateName": "Lactams, Macrocyclic",
"code": {
"@type": "MedicalCode",
"code": "D047029",
"codingSystem": "MeSH"
}
},
"author": [
{
"@type": "Person",
"name": "Jonathan L Sessler",
"url": "https://questionsmedicales.fr/author/Jonathan%20L%20Sessler",
"affiliation": {
"@type": "Organization",
"name": "Department of Chemistry, The University of Texas at Austin, Austin, Texas 78712-1224, United States."
}
},
{
"@type": "Person",
"name": "Chunju Li",
"url": "https://questionsmedicales.fr/author/Chunju%20Li",
"affiliation": {
"@type": "Organization",
"name": "College of Sciences, Center for Supramolecular Chemistry and Catalysis, Shanghai University, Shanghai, 200444, People's Republic of China. cjli@shu.edu.cn."
}
},
{
"@type": "Person",
"name": "Zhongzhen Yang",
"url": "https://questionsmedicales.fr/author/Zhongzhen%20Yang",
"affiliation": {
"@type": "Organization",
"name": "Department of Chemistry, University of York, Heslington York YO10 5DD UK William.unsworth@york.ac.uk."
}
},
{
"@type": "Person",
"name": "Adrian C Whitwood",
"url": "https://questionsmedicales.fr/author/Adrian%20C%20Whitwood",
"affiliation": {
"@type": "Organization",
"name": "Department of Chemistry, University of York, Heslington York YO10 5DD UK William.unsworth@york.ac.uk."
}
},
{
"@type": "Person",
"name": "William P Unsworth",
"url": "https://questionsmedicales.fr/author/William%20P%20Unsworth",
"affiliation": {
"@type": "Organization",
"name": "Department of Chemistry, University of York, Heslington York YO10 5DD UK William.unsworth@york.ac.uk."
}
}
],
"citation": [
{
"@type": "ScholarlyArticle",
"name": "Efficacy and Safety of Upadacitinib vs Dupilumab in Adults and Adolescents with Moderate-to-Severe Atopic Dermatitis: Week 16 results of an Open-label, Randomized, Efficacy Assessor-Blinded Head-to-Head Phase 3b/4 Study (Level Up).",
"datePublished": "2024-10-23",
"url": "https://questionsmedicales.fr/article/39438067",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1093/bjd/ljae404"
}
},
{
"@type": "ScholarlyArticle",
"name": "Safety, Pharmacokinetics and Preliminary Efficacy of IL4-Rα Monoclonal Antibody AK120 in Both Healthy and Atopic Dermatitis Subjects: A Phase I, Randomized, Two-Part, Double-Blind, Placebo-Controlled, Dose-Escalation, First-In-Human Clinical Study.",
"datePublished": "2023-09-05",
"url": "https://questionsmedicales.fr/article/37668898",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1007/s13555-023-01010-1"
}
},
{
"@type": "ScholarlyArticle",
"name": "Early and Sustained Improvements in Symptoms and Quality of Life with Upadacitinib in Adults and Adolescents with Moderate-to-Severe Atopic Dermatitis: 52-Week Results from Two Phase III Randomized Clinical Trials (Measure Up 1 and Measure Up 2).",
"datePublished": "2024-03-25",
"url": "https://questionsmedicales.fr/article/38528257",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1007/s40257-024-00853-4"
}
},
{
"@type": "ScholarlyArticle",
"name": "IgG from Adult Atopic Dermatitis (AD) Patients Induces Nonatopic Neonatal Thymic Gamma-Delta T Cells (γδT) to Acquire IL-22/IL-17 Secretion Profile with Skin-Homing Properties and Epigenetic Implications Mediated by miRNA.",
"datePublished": "2022-06-20",
"url": "https://questionsmedicales.fr/article/35743310",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.3390/ijms23126872"
}
},
{
"@type": "ScholarlyArticle",
"name": "Partial substitution of soybean meal with microalgae meal (Arthrospira spp. - Spirulina) in grower and finisher diets for broiler chickens: implications on performance parameters, footpad dermatitis occurrence, breast meat quality traits, amino acid digestibility and plasma metabolomics profile.",
"datePublished": "2024-05-21",
"url": "https://questionsmedicales.fr/article/38908124",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1016/j.psj.2024.103856"
}
}
],
"breadcrumb": {
"@type": "BreadcrumbList",
"itemListElement": [
{
"@type": "ListItem",
"position": 1,
"name": "questionsmedicales.fr",
"item": "https://questionsmedicales.fr"
},
{
"@type": "ListItem",
"position": 2,
"name": "Composés polycycliques",
"item": "https://questionsmedicales.fr/mesh/D011083"
},
{
"@type": "ListItem",
"position": 3,
"name": "Composés macrocycliques",
"item": "https://questionsmedicales.fr/mesh/D047028"
},
{
"@type": "ListItem",
"position": 4,
"name": "Lactames macrocycliques",
"item": "https://questionsmedicales.fr/mesh/D047029"
}
]
}
},
{
"@type": "MedicalWebPage",
"name": "Article complet : Lactames macrocycliques - Questions et réponses",
"headline": "Questions et réponses médicales fréquentes sur Lactames macrocycliques",
"description": "Une compilation de questions et réponses structurées, validées par des experts médicaux.",
"datePublished": "2025-05-17",
"inLanguage": "fr",
"hasPart": [
{
"@type": "MedicalWebPage",
"name": "Diagnostic",
"headline": "Diagnostic sur Lactames macrocycliques",
"description": "Comment diagnostiquer une infection bactérienne ?\nQuels tests sont utilisés pour les lactames macrocycliques ?\nQuels symptômes indiquent une infection nécessitant des lactames ?\nComment évaluer l'efficacité des lactames macrocycliques ?\nQuels examens d'imagerie sont utiles ?",
"url": "https://questionsmedicales.fr/mesh/D047029?mesh_terms=Dermatitis&page=280#section-diagnostic"
},
{
"@type": "MedicalWebPage",
"name": "Symptômes",
"headline": "Symptômes sur Lactames macrocycliques",
"description": "Quels sont les symptômes d'une infection bactérienne ?\nLes lactames provoquent-ils des effets secondaires ?\nComment reconnaître une réaction allergique ?\nQuels signes d'infection nécessitent une attention médicale ?\nLes lactames macrocycliques affectent-ils le système digestif ?",
"url": "https://questionsmedicales.fr/mesh/D047029?mesh_terms=Dermatitis&page=280#section-symptômes"
},
{
"@type": "MedicalWebPage",
"name": "Prévention",
"headline": "Prévention sur Lactames macrocycliques",
"description": "Comment prévenir les infections bactériennes ?\nLes lactames macrocycliques sont-ils utilisés en prophylaxie ?\nQuelles mesures d'hygiène sont recommandées ?\nLes vaccinations aident-elles contre les infections ?\nComment éviter la résistance aux antibiotiques ?",
"url": "https://questionsmedicales.fr/mesh/D047029?mesh_terms=Dermatitis&page=280#section-prévention"
},
{
"@type": "MedicalWebPage",
"name": "Traitements",
"headline": "Traitements sur Lactames macrocycliques",
"description": "Comment les lactames macrocycliques sont-ils administrés ?\nQuel est le mécanisme d'action des lactames ?\nCombien de temps dure un traitement typique ?\nQuels antibiotiques sont des lactames macrocycliques ?\nComment gérer les effets secondaires des lactames ?",
"url": "https://questionsmedicales.fr/mesh/D047029?mesh_terms=Dermatitis&page=280#section-traitements"
},
{
"@type": "MedicalWebPage",
"name": "Complications",
"headline": "Complications sur Lactames macrocycliques",
"description": "Quelles complications peuvent survenir avec les lactames ?\nComment gérer une surinfection ?\nLes lactames peuvent-ils causer des troubles rénaux ?\nQuels sont les signes d'une réaction sévère ?\nLes lactames macrocycliques peuvent-ils interagir avec d'autres médicaments ?",
"url": "https://questionsmedicales.fr/mesh/D047029?mesh_terms=Dermatitis&page=280#section-complications"
},
{
"@type": "MedicalWebPage",
"name": "Facteurs de risque",
"headline": "Facteurs de risque sur Lactames macrocycliques",
"description": "Quels facteurs augmentent le risque d'infection ?\nLes antécédents d'allergies influencent-ils le traitement ?\nLe mode de vie affecte-t-il le risque d'infection ?\nLes personnes âgées sont-elles plus à risque ?\nLes voyages augmentent-ils le risque d'infections ?",
"url": "https://questionsmedicales.fr/mesh/D047029?mesh_terms=Dermatitis&page=280#section-facteurs de risque"
}
]
},
{
"@type": "FAQPage",
"mainEntity": [
{
"@type": "Question",
"name": "Comment diagnostiquer une infection bactérienne ?",
"position": 1,
"acceptedAnswer": {
"@type": "Answer",
"text": "Le diagnostic repose sur des cultures bactériennes et des tests de sensibilité."
}
},
{
"@type": "Question",
"name": "Quels tests sont utilisés pour les lactames macrocycliques ?",
"position": 2,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des tests de sensibilité aux antibiotiques sont effectués pour évaluer l'efficacité."
}
},
{
"@type": "Question",
"name": "Quels symptômes indiquent une infection nécessitant des lactames ?",
"position": 3,
"acceptedAnswer": {
"@type": "Answer",
"text": "Fièvre, douleur, inflammation et signes d'infection localisée peuvent indiquer une infection."
}
},
{
"@type": "Question",
"name": "Comment évaluer l'efficacité des lactames macrocycliques ?",
"position": 4,
"acceptedAnswer": {
"@type": "Answer",
"text": "L'efficacité est évaluée par l'amélioration clinique et la réduction des cultures positives."
}
},
{
"@type": "Question",
"name": "Quels examens d'imagerie sont utiles ?",
"position": 5,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des radiographies ou IRM peuvent être utilisées pour évaluer des infections profondes."
}
},
{
"@type": "Question",
"name": "Quels sont les symptômes d'une infection bactérienne ?",
"position": 6,
"acceptedAnswer": {
"@type": "Answer",
"text": "Fièvre, frissons, douleur, rougeur et gonflement au site d'infection sont fréquents."
}
},
{
"@type": "Question",
"name": "Les lactames provoquent-ils des effets secondaires ?",
"position": 7,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des effets secondaires comme des éruptions cutanées ou des troubles gastro-intestinaux peuvent survenir."
}
},
{
"@type": "Question",
"name": "Comment reconnaître une réaction allergique ?",
"position": 8,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des démangeaisons, un gonflement ou des difficultés respiratoires peuvent indiquer une allergie."
}
},
{
"@type": "Question",
"name": "Quels signes d'infection nécessitent une attention médicale ?",
"position": 9,
"acceptedAnswer": {
"@type": "Answer",
"text": "Une fièvre élevée persistante ou des douleurs intenses doivent être évaluées par un médecin."
}
},
{
"@type": "Question",
"name": "Les lactames macrocycliques affectent-ils le système digestif ?",
"position": 10,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, ils peuvent causer des nausées, vomissements ou diarrhées chez certains patients."
}
},
{
"@type": "Question",
"name": "Comment prévenir les infections bactériennes ?",
"position": 11,
"acceptedAnswer": {
"@type": "Answer",
"text": "Une bonne hygiène, des vaccinations et un usage prudent des antibiotiques aident à prévenir."
}
},
{
"@type": "Question",
"name": "Les lactames macrocycliques sont-ils utilisés en prophylaxie ?",
"position": 12,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, ils peuvent être utilisés en prophylaxie pour prévenir des infections post-chirurgicales."
}
},
{
"@type": "Question",
"name": "Quelles mesures d'hygiène sont recommandées ?",
"position": 13,
"acceptedAnswer": {
"@type": "Answer",
"text": "Se laver les mains régulièrement et éviter le contact avec des personnes malades sont essentiels."
}
},
{
"@type": "Question",
"name": "Les vaccinations aident-elles contre les infections ?",
"position": 14,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, certaines vaccinations peuvent réduire le risque d'infections bactériennes spécifiques."
}
},
{
"@type": "Question",
"name": "Comment éviter la résistance aux antibiotiques ?",
"position": 15,
"acceptedAnswer": {
"@type": "Answer",
"text": "Utiliser les antibiotiques uniquement lorsque nécessaire et suivre les prescriptions médicales."
}
},
{
"@type": "Question",
"name": "Comment les lactames macrocycliques sont-ils administrés ?",
"position": 16,
"acceptedAnswer": {
"@type": "Answer",
"text": "Ils peuvent être administrés par voie intraveineuse ou orale, selon l'infection."
}
},
{
"@type": "Question",
"name": "Quel est le mécanisme d'action des lactames ?",
"position": 17,
"acceptedAnswer": {
"@type": "Answer",
"text": "Ils inhibent la synthèse de la paroi cellulaire bactérienne, entraînant la mort des bactéries."
}
},
{
"@type": "Question",
"name": "Combien de temps dure un traitement typique ?",
"position": 18,
"acceptedAnswer": {
"@type": "Answer",
"text": "La durée du traitement varie, mais elle est généralement de 7 à 14 jours selon l'infection."
}
},
{
"@type": "Question",
"name": "Quels antibiotiques sont des lactames macrocycliques ?",
"position": 19,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des exemples incluent la méropénème et l'imipénème, utilisés pour des infections graves."
}
},
{
"@type": "Question",
"name": "Comment gérer les effets secondaires des lactames ?",
"position": 20,
"acceptedAnswer": {
"@type": "Answer",
"text": "Il est important de signaler tout effet indésirable au médecin pour ajuster le traitement."
}
},
{
"@type": "Question",
"name": "Quelles complications peuvent survenir avec les lactames ?",
"position": 21,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des réactions allergiques graves ou des infections secondaires peuvent survenir."
}
},
{
"@type": "Question",
"name": "Comment gérer une surinfection ?",
"position": 22,
"acceptedAnswer": {
"@type": "Answer",
"text": "Une évaluation médicale est nécessaire pour ajuster le traitement et cibler la nouvelle infection."
}
},
{
"@type": "Question",
"name": "Les lactames peuvent-ils causer des troubles rénaux ?",
"position": 23,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, certains lactames peuvent affecter la fonction rénale, nécessitant une surveillance."
}
},
{
"@type": "Question",
"name": "Quels sont les signes d'une réaction sévère ?",
"position": 24,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des symptômes comme des difficultés respiratoires ou un gonflement du visage nécessitent une urgence."
}
},
{
"@type": "Question",
"name": "Les lactames macrocycliques peuvent-ils interagir avec d'autres médicaments ?",
"position": 25,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, ils peuvent interagir avec d'autres médicaments, il est donc important d'informer le médecin."
}
},
{
"@type": "Question",
"name": "Quels facteurs augmentent le risque d'infection ?",
"position": 26,
"acceptedAnswer": {
"@type": "Answer",
"text": "L'immunodépression, le diabète et les interventions chirurgicales augmentent le risque."
}
},
{
"@type": "Question",
"name": "Les antécédents d'allergies influencent-ils le traitement ?",
"position": 27,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des antécédents d'allergies aux antibiotiques peuvent limiter les options de traitement."
}
},
{
"@type": "Question",
"name": "Le mode de vie affecte-t-il le risque d'infection ?",
"position": 28,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, un mode de vie sédentaire et une mauvaise alimentation peuvent augmenter le risque."
}
},
{
"@type": "Question",
"name": "Les personnes âgées sont-elles plus à risque ?",
"position": 29,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, les personnes âgées ont un système immunitaire affaibli, les rendant plus vulnérables."
}
},
{
"@type": "Question",
"name": "Les voyages augmentent-ils le risque d'infections ?",
"position": 30,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, les voyages peuvent exposer à des agents pathogènes inconnus, augmentant le risque d'infection."
}
}
]
}
]
}
Atopic dermatitis (AD) is a chronic skin disease characterized by intense itch and eczematous skin lesions. Some patients continue to experience flares and substantial clinical burden despite ongoing ...
This study assessed the efficacy and safety of once-daily upadacitinib (UPA), initiated at 15 mg and dose-escalated to 30 mg based on clinical response, compared with dupilumab (DUPI) per its label. W...
Level Up is a phase 3b/4 global, randomized, open-label, efficacy assessor blinded study evaluating UPA vs DUPI in adolescents and adults with moderate-to-severe AD who had inadequate response to syst...
Superior efficacy in achieving simultaneous EASI 90 and WP-NRS 0/1 response at Week 16 was demonstrated with UPA vs DUPI (19.9% vs 8.9%, respectively; p<0.0001). UPA showed superiority vs DUPI for all...
Treatment of moderate-to-severe AD with UPA, initiated at 15 mg and dose escalated based on clinical response, demonstrated superiority vs DUPI per its label for the primary endpoint of simultaneous a...
Interleukin-4 (IL-4) and interleukin-13 (IL-13) are two essential cytokines involved in the T helper 2 (Th2)-mediated inflammatory response to diseases, such as atopic dermatitis (AD). AK120 is a huma...
The study consisted of two parts. Part 1 was a single ascending dose (SAD) study with five cohorts (receiving 15, 50, 150, 300 or 600 mg of AK120, respectively) of healthy subjects; part 2 was a multi...
The compound was safe and well tolerated in both a SAD up to 600 mg in healthy subjects and in a MAD from 75 to 600 mg in subjects with AD. The exposure of AK120 increased in an approximately dose-dep...
AK120 exhibited an acceptable safety profile in healthy and AD subjects, and showed preliminary efficacy. These findings support the continued investigation of AK120 for treating AD....
ClinicalTrials.gov identification number: NCT04256174....
Atopic dermatitis is a chronic inflammatory disease characterized by increased itch, skin pain, poor sleep quality, and other symptoms that negatively affect patient quality of life. Upadacitinib, an ...
We aimed to evaluate the effect of upadacitinib on patient-reported outcomes over 52 weeks in adults and adolescents with moderate-to-severe atopic dermatitis....
Data from two phase III monotherapy trials of upadacitinib (Measure Up 1, NCT03569293; Measure Up 2, NCT03607422) were integrated. Changes in pruritus, pain, other skin symptoms, sleep, quality of lif...
This analysis included 1609 patients (upadacitinib 15 mg, N = 557; upadacitinib 30 mg, N = 567; placebo, N = 485). Baseline demographics and disease characteristics were generally similar across all a...
Adults and adolescents with moderate-to-severe atopic dermatitis treated with once-daily upadacitinib 15 or 30 mg experienced early improvements in itch, pain, other skin symptoms, sleep, quality of l...
ClinicalTrials.gov identifiers NCT03569293 (13 August 2018) and NCT03607422 (27 July 2018)....
γδT cells mature in the human thymus, and mainly produce IL-17A or IFN-γ, but can also produce IL-22 and modulate a variety of immune responses. Here, we aimed to evaluate whether IgG from AD patients...
This trial was conducted to evaluate the effects of replacing soybean meal with microalgae meal (MM; Arthrospira spp.) during grower and finisher phases on productive performance, footpad dermatitis (...
In young children, atopic dermatitis (AD) imposes a multidimensional burden on many aspects of their quality of life (QoL) and that of their families. LIBERTY AD PRESCHOOL part B was a randomized, dou...
The role of partially hydrolyzed formulas (pHF) as part of nutritional interventions to prevent the development of allergic manifestations (AM) is questioned, and efficacy of each specific pHF should ...
To investigate the risk-reduction effect of a whey-based pHF on the development of cow's milk protein allergy (CMPA) and atopic dermatitis (AD) in infants at high-risk for allergy within the first 6 m...
In a multicenter double-blinded randomized controlled setting, healthy non-exclusively breastfed full-term infants, received either a specific whey-based pHF or a standard cow's milk-based formula (SF...
Of 331 randomized subjects (ITT analysis set), 160 received the pHF and 171 the SF. Six (3.8%) infants in the pHF and 12 (7%) in the SF group developed CMPA (...
This specific whey-based pHF reduced the risk of AD development, particularly in those with a family history of AD, and tended to reduce the development of CMPA in non-exclusively breastfed infants at...
This is the second part of a literature review of the clinical aspects of contact allergy to and allergic contact dermatitis from 2-hydroxyethyl methacrylate (HEMA). Topics include cross- and co-sensi...